<DOC>
	<DOCNO>NCT01009593</DOCNO>
	<brief_summary>The primary objective study ass overall survival ( OS ) oral linifanib give monotherapy daily ( QD ) compare sorafenib give twice daily ( BID ) per standard care subject advance metastatic HCC .</brief_summary>
	<brief_title>Efficacy Tolerability ABT-869 Versus Sorafenib Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>The IDMC recommend discontinuation study , , protocol amend end study treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Neoplasms Histologic Type</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Angiogenesis Modulating Agents</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Inclusion Criteria Histologic cytologic diagnosis unresectable metastatic HCC Child Pugh Class A ECOG performance status 01 Adequate hematologic , hepatic , renal function Exclusion Criteria Prior systemic ( administer intravenously orally rather locoregionally ) treatment HCC Prior local therapy ( include liverdirected therapy ) within 4 week entry Untreated brain meningeal metastases Current treatment another clinical trial Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Growth Substances</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Angiogenesis Inhibitors</keyword>
	<keyword>Inhibitors , Angiogenesis</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Growth Inhibitors</keyword>
	<keyword>Angiogenesis Modulating Agents</keyword>
	<keyword>Sorafenib</keyword>
</DOC>